论文部分内容阅读
目的探索两种不同化疗方案治疗老年血管免疫母细胞性T细胞淋巴瘤的疗效及不良反应。方法 57例老年血管免疫母细胞性T细胞淋巴瘤患者分为两组,其中35例接受标准CHOP方案化疗,22例接受CHOP+培门冬酶方案化疗,定期监测所有患者血常规、肝功能、乳酸脱氢酶、凝血功能、血淀粉酶及血糖。结果 CHOP+培门冬酶方案化疗组完全缓解率和总有效率(27.2%和68.2%)高于标准CHOP方案化疗组(20.0%和62.9%),但差异无统计学意义(P>0.05)。两组不同化疗方案骨髓抑制情况及不良反应发生率差异无统计学意义(P>0.05)。结论 CHOP+培门冬酶联合化疗是安全、有效的治疗措施,在未增加老年血管免疫母细胞性T细胞淋巴瘤不良反应的情况下,可取得与标准CHOP方案化疗近似的疗效。
Objective To explore the efficacy and adverse reactions of two different chemotherapy regimens in the treatment of senile angioimmunoblastic T cell lymphoma. Methods Fifty-seven elderly patients with angioimmunoblastic T cell lymphoma were divided into two groups. 35 patients received standard CHOP chemotherapy and 22 received CHOP + pegaspargase chemotherapy. The blood routine, liver function, lactate Dehydrogenase, coagulation, blood amylase and blood glucose. Results The complete response rate and total effective rate (27.2% and 68.2%) in CHOP plus pemetrexed chemotherapy group were higher than those in standard CHOP chemotherapy group (20.0% and 62.9%, respectively), but the difference was not statistically significant (P> 0.05). There was no significant difference in the incidence of bone marrow suppression and adverse reactions between two groups of different chemotherapy regimens (P> 0.05). Conclusions CHOP + pegaspargase combined with chemotherapy is a safe and effective treatment. Without increasing the adverse reactions of senile angioimmunoblastic T-cell lymphoma, the curative effect similar to that of standard CHOP regimen can be obtained.